Who we are

AMP EXECUTIVE COMMITTEE (EC)

The AMP EC is responsible for the overall AMP program and oversees the steering committees of each AMP disease-specific project. This governance structure allows the program to remain abreast of the ever-evolving science. The AMP EC is responsible for approving new AMP projects and reviewing the progress and milestone achievement of ongoing projects and enables feedback and cross-learning between projects across therapeutic areas. AMP EC meetings are usually held in a closed forum with additional experts invited to participate according to the needs of the EC.

The EC includes leaders from NIH, FDA, and Private Industry/ Non-Profit/Patient Advocacy Co-Chairs from AMP project Steering Committees. The EC convenes quarterly with EC liaison representatives, Office of the Director (OD) liaison representatives, and co-chairs from each of the AMP Project Steering Committees represented on the EC. The AMP PD steering committee EC Liaison is Dr. Walter Koroshetz, Director of NINDS. The AMP PD steering committee OD Liaison is Ellen Gadbois, Lead, Emerging Biotechnology Policy, Office of Science Policy, Office of the Director, National Institutes of Health. The Co-Chairs of AMP PD Steering Committee are Dr. Debra Babcock, Director, Division of Neuroscience Systems and Cognitive Neuroscience Cluster, NINDS and Private Partner Co-Chair Dr. Pablo Sardi (Sanofi).

AMP EXTENDED EXECUTIVE COMMITTEE (EEC)

The AMP EEC meets twice a year and includes the EC members as well as additional private partner representatives from AMP Project Steering Committees (or a proxy representative) to participate in discussions of the latest scientific advancements and the progress of ongoing AMP projects and encourages broad interaction and exchange of ideas among the AMP community.

AMP PD STEERING COMMITTEE (SC)

The AMP PD Steering Committee (SC) will operate under the direction of the AMP Executive Committee (EC) and is responsible for defining and maintaining the research plan for the AMP PD Project, for review of progress of the AMP PD Project, and for the detailed assessment of milestones. The AMP PD Steering Committee provides strong but flexible joint management of the initiative over the five-year implementation of the Research Plan. It allows the partners a mechanism to closely follow the science and the changes in the field for the duration of the partnership, in order to ensure effective results and timely use of resources and assess its progress.

The AMP PD SC is organized by FNIH and is comprised of representatives from the private sector organizations that fund the partnership as well as members from government (NINDS, NIA and FDA). FNIH serves as the non-voting Executive Secretary of the SC and will facilitate the development of meeting agendas and materials under the guidance of the SC Co-Chairs in consultation with the NINDS program officials.

The AMP PD SC is co-chaired by one representative from the NINDS and one member from the AMP PD private sector partners nominated by the SC. The SC may elect to include additional key outside (but non-voting) experts to provide appropriate domain expertise relevant to the research topics. 

The AMP PD SCS has representatives from all AMP PD government partners (NIA, NINDS, FDA), industry partners (Celgene subsidiary of Bristol-Myers Squibb Company, GlaxoSmithKline, Pfizer, Sanofi, and Verily) and the non-profit partners (Aligning Science Across Parkinson’s (ASAP) Initiative and The Michael J. Fox Foundation for Parkinson’s Research).

AMP PD Steering Committee, as of March 2021

Co-chairs

  • Debra Babcock, M.D., Ph.D.
    National Institutes of Health
  • Pablo Sardi, Ph.D., Pharm. D.
    Sanofi

Executive Committee Liaison

  • Walter Koroshetz, M.D.
    National Institutes of Health
    NIH/OD Liaison
  • Ellen Gadbois, Ph.D.
    National Institutes of Health

Public Partner Representatives

  • Billy Dunn, M.D.,
    U.S. Food and Drug Administration
  • Gerald Podskalny, D.O.,
    U.S. Food and Drug Administration
  • Lyn Jakeman, Ph.D., B.A.,
    National Institutes of Health
  • Patrick Bellgowan, Ph.D.,
    National Institutes of Health
  • Suzana Petanceska, Ph.D., B.S.,
    National Institutes of Health

Private Funding Partner Representatives

  • David Glazer, S.B.,
    Verily
  • Ekemini Riley, Ph.D., B.A.,
    Aligning Science Across Parkinson’s (ASAP) Initiative 
  • Guhan Nagapan, Ph.D.
    GlaxoSmithKline
  • Gopi Ganji, Ph.D.
    GlaxoSmithKline
  • Irit Rapley, Ph.D., B.S.,
    Celgene subsidiary of Bristol-Myers Squibb Company
  • Leslie Shinobu, M.D., Ph.D., 
    Celgene subsidiary of Bristol-Myers Squibb Company
  • Robert Moccia, M..D., Ph.D.,
    Pfizer
  • Richard Hargreaves, Ph.D., B.S.,
    Celgene subsidiary of Bristol-Myers Squibb Company
  • Robert Bell, Ph.D., B.S.,
    Pfizer
  • Shameek Biswas, Ph.D., M.Eng.,
    Celgene subsidiary of Bristol-Myers Squibb Company
  • Todd Sherer, Ph.D., B.S.,
    The Michael J. Fox Foundation for Parkinson's Research
  • William Marks, Jr., M.D., M.S.,
    Verily

Managing Partners

  • Eline Appelmans, M.D., M.P.H., BMedSci
    Foundation for the National Institutes of Health

WORKING GROUPS & SUBGROUPS

AMP PD Working Groups and Subgroups are created under the direction of the AMP PD Steering Committee to provide detailed technical guidance for key scientific, policy or informatics issues that arise during implementation of the Research Plan. These Working Subgroups are created and sunsetted based on need, and will operate under one main working group umbrella, the AMP PD Data Working Group or AMP PD Data Analyses Working Group. Like the Steering Committee, the Working Groups and Subgroups will be supported and staffed by an FNIH Program or Project Manager.
At initiation of the working group and subgroups, representatives elected will be invited to a kickoff meeting where the goals of AMP PD and of the specific group are described and discussed. Working group members are invited to nominate those within the working group to public and private co-chair positions.

Working group members are also asked to consider if the relevant expertise is available in the group and if outside expertise is required to drive forward a considered approach. If outside expertise is required, the AMP PD SC is informed of the recommendation. Outside experts are required to share any conflicts of interest with the working group, are recused from final decision making, and may be recused from discussions where they may have conflicts.

The Working Groups and Subgroups focus on specific building blocks required to develop the AMP PD Knowledge Portal with emphasis on data, outreach, policy, and infrastructure.

Of note, the Principal Investigators (PIs) of cohorts contributing data are also invited to have a representative attend working groups relevant to their data contributions. 

Clinical Data Harmonization Subgroup

The Clinical Data Harmonization Subgroup was formed to produce a unified clinical data set that incorporates as many harmonized clinical data elements as possible in a common format that meets CDISC standard.

AMP PD Clinical Data Harmonization Subgroup, as of March 2021

  • Alyssa Reimer (MJFF) – Co-Chair
  • Deb Babcock (NINDS) – Co-Chair 
  • Barry Landin (FNIH Contractor)
  • David Vismer (FNIH Contractor)
  • Eline Appelmans (FNIH)
  • Mary Makarious (NIA/NINDS)
  • Matt Bookman (Verily)
  • Yuliya Kuras (Harvard)

Ad-hoc

  • Nicole Glazer (Celgene/BMS)
  • Robert Moccia (Pfizer) 
  • Deepali Jhamb (GSK)
  • Clemens Scherzer (Harvard)
  • David Pulford (GSK)

Data Analysis Working Group

The Data Analysis Working Group (i) identifies the scientific questions AMP PD would like to address as a consortium; (ii) Defines analyses, tool, and publication priorities; (iii) Reviews publication process and proposals; (iv) Reviews criteria for adding tools to the AMP PD Knowledge Platform.

AMP PD Data Analysis Working Group, as of March 2021

  • Bradford Casey (MJFF) – Co-Chair
  • Hirotaka Iwaki (NIA) – Co-Chair 
  • Alyssa Reimer (MJFF) 
  • Andrew Sharp (MSSM)
  • Andy Singleton (NIA/LNG) 
  • Clemens Scherzer (BWH) 
  • David Alonso (MJFF)
  • David Craig (USC)
  • David Knowles (NYGenome)
  • David Vismer (FNIH Contractor)
  • Debra Babcock (NINDS) 
  • Deepali Jhamb (GSK)
  • Dinesh Kumar (Sanofi)
  • Eline Appelmans (FNIH)
  • Elizabeth Hutchins (TGEN)
  • Erin Teeple (Sanofi)
  • Hampton Leonard (NIA/NINDS)
  • Ivo Violich (USC)
  • Jackie Ward (NINDS)
  • Kendall Jenssen (TGEN) 
  • Mary Makarious (NIA/NINDS)
  • Matt Bookman (Verily)
  • Meaghan Cogswell (Sanofi)
  • Mike Nalls (NIA/NINDS)
  • Ninad Amondikar (MJFF)
  • Ricardo Vialle (MSSM)
  • Rob Woodruff (GSK)
  • Ruifeng Hu  (BWH)
  • Samantha Hutten (MJFF)
  • Shameek Biswas (Celgene/BMS)
  • Srini Shankara (Sanofi)
  • Towfique Raj (MSSM)
  • Xianjun Dong (BWH)

Data Use Policies Subgroup

The Data Use Policies Subgroup works together with the Steering Committee to create AMP PD Governance Documents and works with the other Subgroups to ensure policies are implemented.

AMP PD Data Use Policies Subgroup, as of March 2021

  • Debra Babcock (NINDS) – Co-Chair 
  • Alyssa Reimer (MJFF) – Co-Chair
  • Claire Wegel (IU/GP2)
  • Clemens Scherzer (Harvard)
  • Ekemini Riley (MJFF-ASAP)
  • Eline Appelmans (FNIH)
  • Matt Bookman (Verily)
  • Yuliya Kuras (Harvard)
  • Sonja Scholz (NIA – LBD)
  • Dave Alonso (MJFF – LCC)

Data Working Group

The Data Working Group is made up of other working groups that are part of AMP PD. This WG helps align all other working groups, provides continuity and ultimately makes data related recommendations to the Steering Committee. This, in function, has be partly been replaced by the Data Analyses Working Group as the focus of the program has shifted partially from data generation to data analyses.

AMP PD Data Working Group, as of March 2021

  • Debra Babcock (NINDS) – Co-Chair
  • Matt Bookman (Verily) – Co-Chair
  • Alyssa Reimer (MJFF)
  • Andy Singleton (NIA/LNG)
  • Arthur Toga (USC)
  • Bailin Zhang (Sanofi)
  • Barry Landin (FNIH Contractor)
  • Bradford Casey (MJFF)
  • Codrin Lungu (NINDS)
  • David Craig (USC)
  • Dinesh Kumar (Sanofi)
  • Dongyu Liu (Sanofi)  
  • Eline Appelmans (FNIH) 
  • Erin Teeple (Sanofi)
  • Jackie Ward (NIH)
  • Juan Botia (KCL)
  • Lungu Codrin (NINDS)
  • Mike Nalls (NIA, LNG)
  • Pablo Sardi (Sanofi)
  • Ritu Kapur (Verily)
  • Robert Moccia (Pfizer)
  • Shameek Biswas (Celgene/BMS)
  • Willy Nojopranoto (Verily)

Metabolomics Subgroup

The Metabolomics Subgroup will (i) evaluate the current status of the metabolomics field as it relates to PD and other neurodegenerative diseases; to identify metabolomics technologies that will enrich the AMP PD multi-omic dataset; and to discover metabolomic biomarkers to aid in prognosis with the aim to recommend platform(s)/ scientific directions of interest to AMP PD Steering Committee in the short term and work with grantees on sample selection, data review, quality control, integration, staging, and release.

AMP PD Metabolomics Subgroup, as of March 2021

  • Debra Babcock (NINDS) – Co-Chair
  • Lilu Guo (Sanofi) – Co-Chair 
  • Barry Landin (FNIH Contractor)
  • Chrissa Dwyer (GSK)
  • Eline Appelmans (FNIH)
  • Kevin Jensen (Celgene/BMS)
  • Marcus Bantscheff (GSK)
  • Mark Frasier (MJFF)
  • Suzana Petanceska (NIA)

Ad-hoc

  • Rima Kaddurah-Daouk (Duke) 
  • Michael Schwarzchild (Harvard

 

Outreach and Portal Subgroup

The Outreach portion of this Subgroup will create and AMP PD outreach strategy by defining audiences for targeted outreach efforts, defining outreach priorities, identifying activities, selecting forums to carry out activities, and creating timeline for implementation of a activities
The Portal portion of this Subgroup will create infrastructure and content that is tailored to meet the needs of the AMP PD Portal’s target audiences.

AMP PD Outreach and Portal Subgroup, as of March 2021

  • Jackie Ward (NINDS) – Co-Chair 
  • Nominee Leslie Kirsch (MJFF) – Co-Chair 
  • Abbey Meltzer (FNIH)
  • Carl Wonders (NINDS) 
  • Christine Swanson-Fischer (NINDS)
  • David Alonso (MJFF)
  • Debra Babcock (NINDS)
  • Eline Appelmans (FNIH)
  • Kathleen Parkes (Verily) 
  • Kristine Treece (Sapient)
  • Patrick Bellgowan (NINDS)
  • Sumit Dey (QMUL/GP2)

Ad-hoc

  • Matt Bookman (Verily)
  • Barbara Marebwa (MJFF)
  • Amy Adams (NINDS)
  • Barry Landin (FNIH Contractor)
  • Katherine Thompson (FNIH)
  • Margo Warren (NINDS)
  • Nadia Douaji (NINDS)
  • Ryan Stewart-Frederick (Sapient)

Proteomics Subgroup

The main aim of the Proteomics Subgroup is to develop untargeted and targeted Proteomics data that can be easily accessed and used by researchers to interrogate genes, pathways, and mechanisms that may play a role in disease.

AMP PD Proteomics Subgroup, as of March 2021

  • Debra Babcock (NINDS) – Co-Chair
  • Samantha Hutten (MJFF) – Co-Chair 
  • Amilcar Flores-Morales (Sanofi)
  • Andy Christoforou (Celgene/BMS)
  • Bailin Zhang (Sanofi)
  • Barry Landin (FNIH Contractor)
  • Bradford Casey (MJFF)
  • Christine Swanson-Fischer (NINDS)
  • Eline Appelmans (FNIH)
  • Ethan Xu (Sanofi)
  • Howard Schulman (Allosteros Therapeutics)
  • Lyn Jakeman (NINDS)
  • Marcus Bantscheff (GSK)
  • Pablo Sardi (Sanofi)

Single Cell RNA Sequencing in the Brain Subgroup

This Subgroup will (i) Evaluate current status of the scRNA Seq Brain field as it relates to PD and other neurodegenerative disease; (ii) Identify brain platform technologies that will enrich the AMP PD multi-omic dataset; (iii) Identify brain banks with suitable samples with the aim to recommend platform(s)/ scientific directions of interest to AMP PD Steering Committee in the short term and work with grantees on sample selection, data review, quality control, integration, staging, and release.

AMP PD scRNA Seq Brain Subgroup, as of March 2021

  • Debra Babcock (NINDS) – Co-Chair
  • Kevin Jensen (Celgene/BMS)– Co-Chair 
  • Barry Landin (FNIH Contractor)
  • Bradford Casey (MJFF)
  • Chrissa Dwyer (GSK)
  • Eline Appelmans (FNIH)
  • David Craig (USC)
  • Deepali Jhamb (GSK)
  • Dinesh Kumar (Sanofi)
  • Suzana Petanceska (NIA)

Transcriptomics and Whole Genome Sequencing Subgroup

The main aim of the Transcriptomics portion of this subgroup is to develop a comprehensive RNA resource from whole blood samples that can be easily accessed and used by researchers to interrogate genes, pathways, and mechanisms that may play a role in disease. The overall aims of the whole genome sequencing component of this subgroup are to generate large-scale genetic data, develop and adopt standardized processing and quality control protocols, present the data in a framework that enables browsing and analysis, and integrate the data with all other AMP PD data types.

AMP PD Transcriptomics and Whole Genome Sequencing Subgroup, as of March 2021

  • Andy Singleton (NIA/LNG) – WGS Co-Chair
  • Shameek Biswas (Celgene/BMS) – WGS Co-Chair
  • Kendall Jensen (TGen) – Co-chair
  • Debra Babcock (NINDS) – Co-Chair (Temp)
  • Ashutosh Pandey  (GSK)
  • Barry Landin (FNIH Contractor)
  • Bradford Casey (MJFF)
  • Christine Swanson-Fischer (NINDS) 
  • Daniel Seaton (GSK)
  • David Craig (USC)
  • David Pulford (GSK)
  • David Vismer (FNIH Contractor)
  • Dena Hernandez (NIA)
  • Dinesh Kumar (Sanofi)
  • Dongyu Liu (Sanofi) 
  • Eline Appelmans (FNIH) 
  • Elizabeth Hutchins (TGen) 
  • Guhan Nagappan (GSK) 
  • Hampton Leonard (NIA)
  • Hirotaka Iwaki (NIA)
  • Ivo Violich (USC) 
  • Jerrod Schwartz (Verily)
  • Lyn Jakeman (NINDS)
  • Mark Frasier (MJFF)
  • Mary Makarious (NIA/NINDS)
  • Matt Bookman (Verily)
  • Matt Edwards (Verily)
  • Meaghan Cogswell (Sanofi)
  • Mike Nalls (NIA) 
  • Ramsey Magana (GSK)
  • Robert Moccia (Pfizer) 
  • Robert Woodruff (GSK) 
  • Shawn Levy (Hudson Alpha)
  • Sonja Scholz (NIA)
  • Srini Shankara (Sanofi) 
  • Willy Nojopranoto (Verily)
  • Xianjun Dong (BWH)